USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 5, 2021 | Sep 2021 | $-0.52 | $-0.33 | $-0.69 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 5, 2021 | Sep 2021 | $2.24M | $2.84M | $939.00K |
Gritstone Oncology's next earnings date is Friday, Nov 5, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $-0.52 | $-0.72 | $-0.34 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $-1.25 | $-1.54 | $-0.96 |
| Dec 2022 | 4 | $-2.16 | $-3.93 | $-1.19 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 0 | $-0.54 | $-0.55 | $-0.58 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 0 | $-1.27 | $-1.33 | $-1.53 |
| Dec 2022 | 1 / 0 | $-2.22 | $-2.22 | $-2.44 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $2.24M | $1.00M | $3.25M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $47.01M | $44.54M | $49.04M |
| Dec 2022 | 4 | $24.18M | $5.00M | $68.00M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 5, 2021 | Sep 2021 | $-0.52 | - | - |
| Aug 5, 2021 | Jun 2021 | $-0.62 | $-0.33 | 46.34% |
| May 6, 2021 | Mar 2021 | $-0.58 | $0.10 | 117.39% |
| Mar 11, 2021 | Dec 2020 | $-0.61 | $-0.69 | -13.11% |
| Nov 5, 2020 | Sep 2020 | $-0.62 | $-0.69 | -11.89% |
| Aug 5, 2020 | Jun 2020 | $-0.76 | $-0.69 | 9.21% |
| May 7, 2020 | Mar 2020 | $-0.72 | $-0.71 | 1.93% |
| Mar 11, 2020 | Dec 2019 | $-0.72 | $-0.77 | -6.46% |
| Nov 12, 2019 | Sep 2019 | $-0.65 | $-0.77 | -19.07% |
| Aug 12, 2019 | Jun 2019 | $-0.59 | $-0.63 | -6.78% |
| May 13, 2019 | Mar 2019 | $-0.65 | $-0.62 | 4.13% |
| Mar 28, 2019 | Dec 2018 | $-0.63 | $-0.61 | 2.56% |
| Nov 14, 2018 | Sep 2018 | $-0.57 | $-0.84 | -46.52% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 11, 2021 | Dec 2020 | $-2.68 | $-2.78 | - |
| Mar 11, 2020 | Dec 2019 | $-2.66 | $-2.79 | - |
| Mar 28, 2019 | Dec 2018 | $-2.31 | $-1.45 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 5, 2021 | Sep 2021 | $2.24M | - | - |
| Aug 5, 2021 | Jun 2021 | $2.24M | $2.84M | 1.27% |
| May 6, 2021 | Mar 2021 | $12.21M | $39.69M | 3.25% |
| Mar 11, 2021 | Dec 2020 | $1.21M | $1.35M | 1.11% |
| Nov 5, 2020 | Sep 2020 | $1.06M | $939.00K | 0.89% |
| Aug 5, 2020 | Jun 2020 | $1.23M | $488.00K | 0.40% |
| May 7, 2020 | Mar 2020 | $1.31M | $1.26M | 0.96% |
| Mar 11, 2020 | Dec 2019 | $1.13M | $884.00K | 0.78% |
| Nov 12, 2019 | Sep 2019 | $1.16M | $984.00K | 0.85% |
| Aug 12, 2019 | Jun 2019 | $1.13M | $1.15M | 1.02% |
| May 13, 2019 | Mar 2019 | $960.00K | $1.35M | 1.40% |
| Mar 28, 2019 | Dec 2018 | $1.42M | $1.09M | 0.77% |
| Nov 14, 2018 | Sep 2018 | $1.50M | $96.00K | 0.06% |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 11, 2021 | Dec 2020 | $3.89M | $4.04M | 3.78% |
| Mar 11, 2020 | Dec 2019 | $4.37M | $4.37M | -0.11% |
| Mar 28, 2019 | Dec 2018 | $2.70M | $1.19M | -56.04% |
GRTS's next earnings date is Friday, Nov 5, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 4 analysts, the average EPS estimation for Gritstone Oncology's next quarterly earnings is $-0.52, with a low EPS estimation of $-0.66, and a high estimation of $-0.38.
Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $-0.53, the last 2 month trend is $-0.54, and the 3 month trend is $-0.59.
Based on 4 analysts, the average revenue estimation is $2.24M, with a low revenue estimation of $1.00M, and a high estimation of $3.25M.
Gritstone Oncology's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.
GRTS's earnings per share (EPS) was $-0.33, beating the consensus analysts forecast of $-0.62 by 46.34%.
The EPS was lower than the previous fiscal quarter (Mar 2021) by -430.00%, and higher than the same period a year before (Jun 2020) by -52.17%.
Revenues were $2.84M, better than the forecast of $2.24M by 26.92%, down by -92.84% from the previous quarter , and up by 482.58% from the same period last year.
The company reported a net income of $-25.12M.Free cash flow for the quarter was $-24.35M , compared to $9.66M last quarter and $-21.75M a year before.
GRTS ended the quarter with $22.35M in total debt, a decrease of -5.68% compared to the previous quarter, and a decrease of -15.67% compared to the same quarter a year before.
Gritstone Oncology's previous annual earnings date was Mar 11, 2021 for its fiscal year ended Dec 31, 2020.
GRTS's earnings per share (EPS) was $-2.78, missing the consensus analysts forecast of $-2.68 by 3.73% , and higher than the previous year's EPS (Dec 2019) by -0.36%.
Revenues were $4.04M, better than the forecast of $3.89M by 3.78%, and down by -7.51% from previous year's revenue.
The company reported a net income of $-105.31M.
Gritstone Oncology reported a free cash flow of $-92.62M for its fiscal year, compared to $-101.18M a year ago.
The company ended the fiscal year with $25.10M in total debt, an increase of 6.85% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.